Skip to main content

Table 1 Baseline demographic and clinical features of the placebo and treatment groups

From: Placebo-controlled randomized clinical trial of fish oil’s impact on fatigue, quality of life, and disease activity in Systemic Lupus Erythematosus

 

All

Completers

 

Placebo (N=25)

Fish oil (N=25)

Placebo (N=14)

Fish oil (N=18)

Demographics

    

 Sex, female

22 (88 %)

20 (80 %)

11 (79 %)

14 (78 %)

 Age, years

36.1 [28.6–41.0]a

46.1 [34.7–49.3]a

35.6 [26.3–42.7]a

46.2 [36.8–49.1]a

Ethnicity

    

 Hispanic/Latino

11 (44 %)

11 (44 %)

7 (50 %)

8 (44 %)

 Black/African American

13 (52 %)

14 (56 %)

6 (43 %)

10 (56 %)

 White

1 (4 %)

0 (0 %)

1 (7 %)

0 (0 %)

BMI

25.0 [23.4–32.6]a

31.4 [27.5–40.2]a

26.0 [23.7–33.0]a

35.4 [29.0–42.0]a

Rate Your Plate

55 [50–60]

57 [52–63]

56 [50–61]

58 [53–64]

Comorbidities

    

 HTN

13 (52 %)a

20 (8O%)a

6 (43 %)a

15 (83 %)a

 DM2

1 (4 %)

6 (24 %)

1 (7 %)

4 (22 %)

 Tobacco Use

5 (20 %)

7 (28 %)

5 (36 %)

6 (33)%

Disease Characteristics

    

 SELENA-SLEDAI

8 [2–10]

6 [3–10.5]

4 [0–3.5]

7 [3.5–11.25]

 Disease duration, years

6 [2–10]

6 [3–11]

5.5 [l.8–9.3]

6 [2.8–10.5]

 ACR Criteria, total number

6 [5–7]

5 [5–7]

5 [4–7]

5.5 [5–7]

 Lupus Nephritis

18 (72 %)

17 (68 %)

10 (71 %)

14 (78 %)

Medication

    

Prednisone

    

 0 mg/day

7 (28 %)

11 (44 %)

5 (36 %)

7 (39 %)

 ≤7.5 mg/day

8 (32 %)

4 (16 %)

5 (36 %)

2 (11 %)

 >7.5 mg/day

10 (40 %)

10 (40 %)

4 (29 %)

9 (50 %)

Hydroxychloroquine

22 (88 %)

22 (88 %)

12 (86 %)

16 (89 %)

Other Immunosuppressants

    

 Cyclophosphamide

0 (0 %)

2 (8 %)

0 (0 %)

1 (6 %)

 Mycophenolate

11 (44 %)

11 (44 %)

8 (57 %)

7 (39 %)

 Azathioprine

4 (16 %)

1 (4 %)

2 (14 %)

0 (0 %)

Misc. Medications

    

 Statin

5 (20 %)

8 (32 %)

2 (14 %)

7 (39 %)

 ACEI/ARB

16 (64 %)

15 (60 %)

9 (64 %)

12 (67 %)

  1. Characteristics of the fish oil treatment group and olive oil placebo group, for both the intial randomized patient groups (N=50) and the completers (N=32). Data presented as number of patients (%) or median and interquartile range [IQ.R]. Statistically significant differences (p<0.05) comparing fish oil and placebo groups are indicated with a superscript a(a)